Literature DB >> 28533125

Markers of immune-mediated inflammation in the brains of young adults and adolescents with type 1 diabetes and fatal diabetic ketoacidosis. Is there a difference?

William H Hoffman1, Carol M Artlett2, Dallas Boodhoo3, Mary G F Gilliland4, Luis Ortiz5, Dries Mulder6, David H T Tjan7, Alvaro Martin3, Alexandru Tatomir3, Horea Rus8.   

Abstract

Due to the limited data on diabetic ketoacidosis and brain edema (DKA/BE) in children/adolescents and the lack of recent data on adults with type 1 diabetes (T1D), we addressed the question of whether neuroinflammation was present in the fatal DKA of adults. We performed immunohistochemistry (IHC) studies on the brains of two young adults with T1D and fatal DKA and compared them with two teenagers with poorly controlled diabetes and fatal DKA. C5b-9, the membrane attack complex (MAC) had significantly greater deposits in the grey and white matter of the teenagers than the young adults (p=0.03). CD59, a MAC assembly inhibitory protein was absent, possibly suppressed by the hyperglycemia in the teenagers but was expressed in the young adults despite comparable average levels of hyperglycemia. The receptor for advanced glycation end products (RAGE) had an average expression in the young adults significantly greater than in the teenagers (p=0.02). The autophagy marker Light Chain 3 (LC3) A/B was the predominant form of programmed cell death (PCD) in the teenage brains. The young adults had high expressions of both LC3A/B and TUNEL, an apoptotic cell marker for DNA fragmentation. BE was present in the newly diagnosed young adult with hyperglycemic hyperosmolar DKA and also in the two teenagers. Our data indicate that significant differences in neuroinflammatory components, initiated by the dysregulation of DKA and interrelated metabolic and immunologic milieu, are likely present in the brains of fatal DKA of teenagers when compared with young adults.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain edema; C5b-9; Diabetic ketoacidosis; Neuroinflammation; Receptor for advanced glycation end products; Type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28533125     DOI: 10.1016/j.yexmp.2017.05.013

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  3 in total

1.  Successful Treatment of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Status in an Infant with KCNJ11-Related Neonatal Diabetes Mellitus via Continuous Renal Replacement Therapy.

Authors:  Ting Chen; Dandan Zhang; Zhenjiang Bai; Shuiyan Wu; Haiying Wu; Rongrong Xie; Ying Li; Fengyun Wang; Xiuli Chen; Hui Sun; Xiaoyan Wang; Linqi Chen
Journal:  Diabetes Ther       Date:  2018-08-09       Impact factor: 2.945

2.  Impact of Early Diabetic Ketoacidosis on the Developing Brain.

Authors:  Tandy Aye; Paul K Mazaika; Nelly Mauras; Matthew J Marzelli; Hanyang Shen; Tamara Hershey; Allison Cato; Stuart A Weinzimer; Neil H White; Eva Tsalikian; Booil Jo; Allan L Reiss
Journal:  Diabetes Care       Date:  2018-12-20       Impact factor: 19.112

3.  Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes.

Authors:  William H Hoffman; Stephen A Whelan; Norman Lee
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.